Healthcare Testing Services Market
Healthcare testing services are invented, and developed in the laboratories. During pharmaceutical production and research and development, healthcare testing in labs is required at practically every stage including preclinical, clinical, and manufacturing. It is used to test raw materials and to perform an in-process quality control (IPQC) of dosage forms and finished products. Healthcare testing aids in assessing a medical product's safety, efficacy, stability, and dosage potency. Before releasing a product in the market, a healthcare testing laboratory can assist in testing to ensure that it is safe to use. Chemical testing, microbiological testing, toxicological testing, stability testing, and other services are just a few services that healthcare testing laboratories offer to guarantee the safety of medications and treatments.
Market Dynamics
Complex research and development procedures, stringent government regulations regarding product compliance, increasing product approvals by regulatory authorities, and launches of novel services and products are the major factors that are expected to drive the growth of the global healthcare testing services market over the forecast period.
Moreover, increasing number of funding initiatives by government and research organizations to provide funding to pharmaceutical and medical device manufacturing companies in order to develop drugs and diagnostic kits for the treatment of novel coronavirus, increasing research and development activities, and rising number of clinical trials owing to the COVID-19 outbreak are expected to create lucrative opportunities in the market. Many research organizations and government agencies are funding pharmaceutical and medical device manufacturing companies for the development of kits for diagnosis and drugs, and for the treatment of the novel coronavirus.
For instance, in April 2020, Moderna Inc., a clinical-stage biotechnology company, received US$ 483 million funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for rapid development of Moderna’s mRNA vaccine candidate (mRNA-1273) against the SARS-CoV-2 coronavirus. The funding will be through Phase II and III clinical trials to United States Food and Drug Administration (FDA) licensure.
Key features of the study
Market Segmentation
Table of Contents
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
